Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to drug resistance in tough colorectal cancer

NCT ID NCT07617610

Knowledge-focused Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study looks at why a specific type of advanced colorectal cancer (with a BRAF V600E mutation) becomes resistant to standard targeted therapy. Researchers will collect tumor tissue, blood, and stool samples from 30 patients before treatment and when the disease progresses. They will also grow mini-tumors in the lab to test new ways to overcome resistance. The goal is to gather knowledge that could lead to more effective treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Longitudinal translational sampling (tumor tissue, blood, stool) and patient-derived organoids
What this could lead to
If successful, this could reveal why current treatments stop working and point toward new drug combinations to overcome resistance.
What could go wrong
This is an early-stage observational study with only 30 participants, so findings may not apply to all patients. It does not test a new treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from oncology centers across Switzerland participating in the Swiss Group for Clinical Cancer Research (SAKK). The study population consists of adult patients with metastatic colorectal cancer treated in routine clinical practice at tertiary care and regional cancer centers. Eligible patients are identified by their treating oncologists at participating sites and enrolled prior to initiation of standard-of-care systemic therapy. Recruitment is limited to centers with access to molecular diagnostics and the capability to perform tumor biopsies and longitudinal sample collection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of unresectable or metastatic BRAF V600E-mutated colorectal cancer * Planned initiation of treatment with combined anti-EGFR antibody and BRAF inhibitor * Patients receiving treatment in any line, with or without chemotherapy * At least one tumor lesion accessible for biopsy * ECOG performance status 0-2 * Life expectancy of at least 3 months * Age ≥18 years * Ability to provide written informed consent Exclusion Criteria: * Medical or surgical contraindication for tumor biopsy * Active second malignancy (except non-melanoma skin cancer) * Inability to comply with study procedures (e.g., due to language barriers or cognitive impairment) * Pregnancy or breastfeeding * Previous treatment with a BRAF inhibitor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF V600E mutation Metastatic colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Bürgerspital Solothurn

    RECRUITING

    Solothurn, 4500, Switzerland

  • HFR Freiburg - Kantonsspital

    RECRUITING

    Villars-sur-Glâne, 1752, Switzerland

  • HOCH Health Ostschweiz - Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Inselspital Bern

    RECRUITING

    Bern, 3010, Switzerland

  • Kantonsspital Aarau

    RECRUITING

    Aarau, CH-5000, Switzerland

  • Kantonsspital Baden

    RECRUITING

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Winterthur

    RECRUITING

    Winterthur, 8004, Switzerland

  • Luzerner Kantonsspital

    RECRUITING

    Lucerne, 6004, Switzerland

  • Spitalzentrum Biel - MEDIN La Tour

    RECRUITING

    Biel, 2502, Switzerland

  • St. Claraspital

    RECRUITING

    Basel, 4058, Switzerland

  • Universitaetsspital Basel

    RECRUITING

    Basel, CH-4031, Switzerland

  • Universitätsspital Zürich USZ

    RECRUITING

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.